-
Tytuł:
-
[The role of proton therapy in esophageal cancer].
-
Autorzy:
-
Créhange G; Département d'oncologie radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France; Département d'oncologie radiothérapie (Centre de Protonthérapie), institut Curie, Orsay, France; Département d'oncologie radiothérapie, institut Curie, 92, boulevard Dailly, Saint-Cloud, France. Electronic address: .
Goudjil F; Département d'oncologie radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France; Département d'oncologie radiothérapie (Centre de Protonthérapie), institut Curie, Orsay, France.
Krhili SL; Département d'oncologie radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France.
Minsat M; Département d'oncologie radiothérapie, institut Curie, 92, boulevard Dailly, Saint-Cloud, France.
de Marzi L; Département d'oncologie radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France; Département d'oncologie radiothérapie (Centre de Protonthérapie), institut Curie, Orsay, France; Département d'oncologie radiothérapie, institut Curie, 92, boulevard Dailly, Saint-Cloud, France; Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Campus universitaire, Orsay 91898, France.
Dendale R; Département d'oncologie radiothérapie, institut Curie, 25, rue d'Ulm, 75005 Paris, France; Département d'oncologie radiothérapie (Centre de Protonthérapie), institut Curie, Orsay, France.
-
Transliterated Title:
-
Le rôle de la protonthérapie dans les cancers de l’oesophage.
-
Źródło:
-
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Jun; Vol. 26 (4), pp. 604-610. Date of Electronic Publication: 2021 Oct 20.
-
Typ publikacji:
-
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
-
Język:
-
French
-
Imprint Name(s):
-
Original Publication: Paris : Elsevier, c1997-
-
MeSH Terms:
-
Esophageal Neoplasms*/pathology
Esophageal Neoplasms*/radiotherapy
Proton Therapy*/adverse effects
Radiotherapy, Intensity-Modulated*/adverse effects
Radiotherapy, Intensity-Modulated*/methods
Re-Irradiation*
Humans ; Protons ; Radiotherapy Dosage ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: Cancer de l’œsophage; Chemoradiotherapy; Chimioradiothérapie; Esophageal cancer; Proton therapy; Protonthérapie; Review; Revue
-
Substance Nomenclature:
-
0 (Protons)
-
Entry Date(s):
-
Date Created: 20211024 Date Completed: 20220602 Latest Revision: 20220602
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.canrad.2021.08.015
-
PMID:
-
34688549
-
Because of the physical properties of proton beam radiation therapy (PT), which allows energy to be deposited at a specific depth with a rapid energy fall-off beyond that depth, PT has several theoretical advantages over photon radiation therapy for esophageal cancer (EC). Protons have the potential to reduce the dose to healthy tissue and to more safely allow treatment of tumors near critical organs, dose escalation, trimodal treatment, and re-irradiation. In recent years, larger multicenter retrospective studies have been published showing excellent survival rates, lower than expected toxicities and even better outcomes with PT than with photon radiotherapy even using IMRT or VMAT techniques. Although PT was associated with reduced toxicities, postoperative complications, and hospital stays compared to photon radiation therapy, these studies all had inherent biases in relation with patient selection for PT. These observations were recently confirmed by a randomized phase II study in locally advanced EC that showed significantly reduced toxicities with protons compared with IMRT. Currently, two randomized phase III trials (NRG-GI006 in the US and PROTECT in Europe) are being conducted to confirm whether protons could become the standard of care in locally advanced and resectable esophageal cancers.
(Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)
